# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-050452
Filing Date
2022-04-26
Accepted
2022-04-26 17:19:03
Documents
5
Period of Report
2022-06-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm223590-1_def14a.htm | DEF 14A | 672716
2 | GRAPHIC | tm223590d1-pxy_proxy1bw.jpg | GRAPHIC | 830302
3 | GRAPHIC | tm223590d1-pxy_proxy2bw.jpg | GRAPHIC | 770452
4 | GRAPHIC | tm223590d1-pxy_proxy3bw.jpg | GRAPHIC | 686144
5 | GRAPHIC | tm223590d1-pxy_proxy4bw.jpg | GRAPHIC | 647357
| Complete submission text file | 0001104659-22-050452.txt |  | 4707529

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 22855423
SIC: 2834 Pharmaceutical Preparations